IDL Biotech has submitted supporting documents to the US FDA (Food and Drug Administration) to be able to obtain future approval of UBC® Rapid, the company’s rapid test for bladder cancer.
Read the press release here (in swedish)
An abstract presented in Tumor Biology (July 2019: 1-74) shows the value of UB® Rapid, for accurate diagnosis and follow-up in bladder cancer. Read the press release here (in swedish)
International Journal of Molecular Sciences has published a study on UBC® Rapid. In total 530 urine samples was included in the multicenterstudy. The author of the study concluded that elevated values of UBC® Rapid Test in urine are higher in patients with...
Bladder cancer is the ninth most commonly diagnosed cancer in the world with an estimated 430 000 new cases reported in 2012. Men are more than three times more likely to get bladder cancer than women. Smoking is a major cause of bladder cancer. Exposure to industrial...
